Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Guselkumab Assessment in Moderate-to-Severe Inflammatory Bowel Disease (IBD) Observational Study in a Real Life Italian Setting

NCT07851207 is registered in ClinicalTrials.gov with Janssen-Cilag Ltd. as lead sponsor.

NCT NCT07851207
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07851207 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Guselkumab Assessment in Moderate-to-Severe Inflammatory Bowel Disease (IBD) Observational Study in a Real Life Italian Setting
Lead sponsor
Janssen-Cilag Ltd.
Phase
Observational
Overall status
Not yet recruiting
Start date
October 5, 2026
Completion date
July 31, 2029
Enrollment
200 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

colitis, ulcerative, crohn disease, inflammatory bowel diseases